Tags

Type your tag names separated by a space and hit enter

Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation.
Eur J Intern Med. 2020 06; 76:21-22.EJ

Authors+Show Affiliations

University College London Hospitals NHS Foundation Trust, Department of Medicine, London, UK; Cardio-metabolic Programme-NIHR UCLH/UCL BRC, London, UK. Electronic address: marcel.levi@nhs.net.

Pub Type(s)

Journal Article
Comment

Language

eng

PubMed ID

32425364

Citation

Levi, Marcel. "Tocilizumab for Severe COVID-19: a Promising Intervention Affecting Inflammation and Coagulation." European Journal of Internal Medicine, vol. 76, 2020, pp. 21-22.
Levi M. Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation. Eur J Intern Med. 2020;76:21-22.
Levi, M. (2020). Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation. European Journal of Internal Medicine, 76, 21-22. https://doi.org/10.1016/j.ejim.2020.05.018
Levi M. Tocilizumab for Severe COVID-19: a Promising Intervention Affecting Inflammation and Coagulation. Eur J Intern Med. 2020;76:21-22. PubMed PMID: 32425364.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation. A1 - Levi,Marcel, Y1 - 2020/05/16/ PY - 2020/05/10/received PY - 2020/05/11/accepted PY - 2020/5/20/pubmed PY - 2020/6/11/medline PY - 2020/5/20/entrez SP - 21 EP - 22 JF - European journal of internal medicine JO - Eur J Intern Med VL - 76 SN - 1879-0828 UR - https://www.unboundmedicine.com/medline/citation/32425364/Tocilizumab_for_severe_COVID_19:_A_promising_intervention_affecting_inflammation_and_coagulation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0953-6205(20)30204-1 DB - PRIME DP - Unbound Medicine ER -